All Oncology News

In a phase 1b/2 study, copanlisib plus rucaparib was well tolerated and show antitumor activity at the RP2D in mCRPC.

Obe-cel produced responses and low rates of high-grade CRS and ICANS in pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Tafasitamab/lenalidomide added to first-line R-CHOP improved PFS vs R-CHOP alone with no new safety signals in patients with DLBCL.

Cardiac surgery and airway reconstruction successfully treated rare cancer that spread to a patient's heart according to researchers at Mayo Clinic.

Cassie Kline, MD, MAS, discusses data from the phase 2 FIREFLY-1 trial of tovorafenib in relapsed/refractory pediatric low-grade glioma.

Embracing the consistency of change allowed Michael Andreeff, MD, PhD, to earn his title as a 2025 Giants of Cancer Care inductee in Translational Science.

The top 5 OncLive TV videos of the week cover insights in leukemia, lung cancer, multiple myeloma, indolent systemic mastocytosis, and pancreatic cancer.

Jason Mouabbi, MD, discusses the emerging role of ctDNA tests in breast cancer management and their use in early detection and treatment monitoring.

With her collaborative ethos and patient-first focus, Lisa A. Carey, MD, ScM, FASCO, is driving innovation in breast cancer research and management.

The FDA cleared narsoplimab for TA-TMA, an NDA seeking approval of bezuclastinib in nonadvanced systemic mastocytosis has been submitted, and more.

Maurie Markman, MD, discusses the essential yet often complex role associated with interpreting numbers and measurements in oncology.

China’s NMPA approved ipilimumab N01 plus sintilimab as neoadjuvant therapy for stage IIB to III resectable MSI-H/dMMR colon cancer.

The FDA has received a new drug application seeking the approval of bezuclastinib for the treatment of patients with non-advanced systemic mastocytosis.

Saad Z. Usmani, MD, MBA, FACP, FASCO, is renowned leader whose work has helped redefine treatment standards and extend the lives of patients worldwide.

Investigators at Dana-Farber Cancer Institute have developed an AI-based noninvasive tool that can predict the likelihood of oropharyngeal cancer spread.

Japan’s Ministry of Health, Labour and Welfare has approved tafasitamab plus rituximab and lenalidomide for relapsed/refractory follicular lymphoma.

Lodovico Balducci, MD, built a new discipline from the ground up, which kick-started pivotal research in geriatric oncology.

NXC-201 demonstrated organ responses in 70% of evaluable patients with relapsed/refractory light chain amyloidosis.

In case you missed any, read a recap of every episode of OncLive On Air that aired in December 2025.

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for recurrence.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in December 2025 spanning tumor types.

T-cell redirecting therapies can be safely monitored within the home of patients, limiting hospital visits according to researchers at Fox Chase.

Franco Cavalli, MD, has dedicated his life to treating patients, developing drugs, and bringing higher quality cancer care to areas in need of improvement

The FDA has approved narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Kenneth Offit, MD, MPH, is a pioneering cancer geneticist whose groundbreaking work has shaped how hereditary cancer is understood, prevented, and managed.

Real-world elranatamab led to higher response rates despite less favorable baseline characteristics vs real-world teclistamab in R/R multiple myeloma.

Most premenopausal women with early breast cancer accepted GnRHa during chemotherapy to preserve ovarian function; cryopreservation uptake was lower.

Researchers at Northwestern Medicine have developed a new and faster approach to determine if a treatment for the brain cancer glioblastoma is working.

A focus on her passion for leukemia research and genuine care for her patients enabled Wendy Stock, MD, to rise above—one step at a time—as a mentor, leader, and pioneer.

A mobile health intervention was associated with improvements to general and cancer-specific quality of life in AYA breast cancer survivors.